RE:RE:RE:RE:I'm so sexcitedQquattro, you scummie, nice minimizing soft bash of the jv, tell us how your pp would have been better, you big scummie bag of pooh!
Quattro74 wrote: Laser, I hope that TLT gets the money from the GBM indication to move forward using this jv. The main problem I have with this is what % do they give up, from this indication, to get the $20M or so they need to get across the finish line?? It seems that in this PR they are downplaying(being conservative?) their own efficacy expectations to make the combined treatment seem more effective, % wise, than it would otherwise be. Only 10% effective on GBM?? Really?? I think most here would expect a higher success rate for TLT's tech. But we are speaking of GBM, and that is the most difficult indication to rid.
LaserStock29 wrote: Dr. Mandel concluded by saying that, “This latest preclinical research lays the groundwork for the Company to actively seek strategic partnerships in the co-development of this combined technology for the treatment of specific human cancers, such as GBM. The Company plans to explore these avenues in the immediate future, with the hopes of securing a joint venture with a company interested in the development of this combination technology, such as a Canadian cannabis producer.”
You know what PP stands for at this stage of the game.. Pick Pocket. lol
TLD-1433
DFOC
Full Monte
TLD-1633
NMIBC P1, GBM Preclin, Lung Preclin
TLC-2000 and Warburg effect
Now add in CBD.
Im probably missing some assets
Like petri dish on Colon, Bronchio, Cervical cancers 90-97% kill rate
Two words i love
Discover Develop.... 50m front, 500m backend (incentivized)
$$$$$$